Influenza Virus Challenge for Flu
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial involves giving healthy adults a small dose of the H10N7 flu virus. Researchers will observe how their bodies respond to help develop better flu vaccines.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, it does exclude individuals with certain medical conditions and those who have received specific treatments recently, so it's best to discuss your medications with the trial team.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you have a significant medical condition or are taking certain medications like long-term aspirin therapy, you may be excluded from participating.
How is the drug A/Mallard/Ohio-99/MM4/1989 H10N7 different from other flu treatments?
The drug A/Mallard/Ohio-99/MM4/1989 H10N7 is unique because it involves a low pathogenicity avian influenza virus, which is not typically used in standard flu treatments. This approach may offer insights into how avian influenza viruses interact with hosts and could potentially inform the development of new strategies for managing flu infections.12345
How does the treatment A/Mallard/Ohio-99/MM4/1989 H10N7 differ from other flu treatments?
The treatment A/Mallard/Ohio-99/MM4/1989 H10N7 is unique because it involves using a low pathogenicity avian influenza virus, which is not a standard approach for treating flu in humans. This treatment is different from typical antiviral drugs like oseltamivir (Tamiflu) that target human-adapted flu strains.12345
What data supports the effectiveness of the treatment A/Mallard/Ohio-99/MM4/1989 H10N7 for flu?
The research indicates that low pathogenic avian influenza viruses, like H10N7, can trigger a strong but short-lived immune response in mallards, suggesting that the virus may be controlled effectively by the immune system. Additionally, similar H10N7 viruses have been involved in outbreaks, indicating their ability to cause infection, which may imply potential for vaccine development.15678
What data supports the effectiveness of the treatment A/Mallard/Ohio-99/MM4/1989 H10N7 for flu?
The research shows that low pathogenic avian influenza viruses, like H10N7, can trigger a strong but short-lived immune response in mallards, which are natural hosts. This suggests that the virus may be controlled effectively by the immune system, potentially indicating a similar response in humans.15678
Who Is on the Research Team?
Matthew J Memoli, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)
Are You a Good Fit for This Trial?
Healthy adults aged 18-50 who can consent and agree to stay in isolation for at least 10 days without using tobacco, marijuana, or vaping. Women must meet specific fertility and HIV criteria; men must meet certain fertility conditions. Excludes those with significant medical issues, high-risk contacts, abnormal test results, recent illness or vaccinations, drug/alcohol abuse, psychiatric problems, non-English speakers.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Inoculation and Monitoring
Participants are inoculated with one dose of the flu virus and monitored 24 hours a day in an isolation room for at least 10 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with at least 4 follow-up visits over 8 weeks.
What Are the Treatments Tested in This Trial?
Interventions
- A/Mallard/Ohio-99/MM4/1989 H10N7
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor